Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients.

about

Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients.

Item

http://www.wikidata.org/entity/Q54225107

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Prevalence of and risk factors ...... treated HIV-infected patients.

@en

Prevalence of and risk factors ...... treated HIV-infected patients.

@nl

type

Item

label

Prevalence of and risk factors ...... treated HIV-infected patients.

@en

Prevalence of and risk factors ...... treated HIV-infected patients.

@nl

prefLabel

Prevalence of and risk factors ...... treated HIV-infected patients.

@en

Prevalence of and risk factors ...... treated HIV-infected patients.

@nl

P1476

Prevalence of and risk factors ...... treated HIV-infected patients

@en

P2093

Concepción García-Lacalle

http://www.w3.org/2001/XMLSchema#string

Jose Luís Agud

http://www.w3.org/2001/XMLSchema#string

Juan José Jusdado

http://www.w3.org/2001/XMLSchema#string

Rafael Torres

http://www.w3.org/2001/XMLSchema#string

Santiago Moreno

http://www.w3.org/2001/XMLSchema#string

Victoria Alcázar

http://www.w3.org/2001/XMLSchema#string

P2860

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

Incident fractures in HIV-infected individuals: a systematic review and meta-analysis

Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.

Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

HIV infection--a risk factor for osteoporosis.

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.

HIV and bone disease.

P304

e0196201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0196201

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Miguel Cervero

P577

2018-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29709013

http://www.w3.org/2001/XMLSchema#string

P932

5927434

http://www.w3.org/2001/XMLSchema#string